Baxter International will partner with ScinoPharm Taiwan to develop, manufacture, and commercialize five injectable generic drugs for oncology and chemotherapy-related indications, the companies said today, through a collaboration whose value was not disclosed.

The companies said the five drugs will consist of a range of cancer treatments—including lung cancer, multiple myeloma, and breast cancer—as well as therapies for chemotherapy-related nausea and vomiting.

The products will be generic versions of branded drugs that generate more than $4 billion annually, Baxter and ScinoPharm said, without detailing the branded products involved. ScinoPharm will provide APIs for the initial five generic injectables, while sharing manufacturing responsibilities with Baxter.

The majority of the molecules will be manufactured at Baxter’s plant in Halle, Germany, the companies said.

“The ScinoPharm collaboration will further expand Baxter’s presence in generic injectables, which will continue to be enhanced through our recently executed agreement to acquire Claris Injectables,” Robert Felicelli, president, Pharmaceuticals, Baxter, said in a statement.

Baxter said in December it is acquiring Claris Lifesciences’ generic injectables subsidiary for approximately $625 million—a deal the buyer said February 1 it still expects will close in the second half of this year. Baxter says the acquisition will provide it with a currently marketed portfolio of molecules in anesthesia and analgesics, renal, anti-infectives, and critical care, along with a pipeline it calls robust, and manufacturing capabilities.

That, in turn, will expand Baxter’s presence in global generic injectable pharmaceuticals, among the company’s areas of focus since spinning out its Baxter BioScience global biopharmaceutical business into Baxalta in 2015. Baxalta was  acquired last year by Shire for $32 billion.

“Combining Baxter’s differentiated manufacturing expertise and global commercialization capabilities with ScinoPharm’s recognized API experience enables Baxter to increase patient access to difficult-to-manufacture, high-quality oncolytic medicines,” Felicelli added.

The five generics will join Baxter’s existing portfolio of generic injectable treatments, which include oncology drugs as well as anti-infectives, analgesics, and critical care medicines.

In addition to the five products, Baxter holds an option to partner with ScinoPharm on as many as 15 additional injectable molecules.

Baxter will hold commercialization rights, with products covered by the partnership expected to launch starting in 2020.

“This strategic partnership will boost our expansion in the formulation business, increase market coverage of our products, and eventually fuel our further operating performance,” stated ScinoPharm CEO Yung-Fa Chen, Ph.D.